Prior antipsychotic prescribing in patients currently receiving clozapine: A case note review

Journal of Clinical Psychiatry

Volumn 64, Issue 1, 2003, Pages 30-34

  Taylor, David M ^a   Young, Corina ^a   Paton, Carol ^b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b OXLEAS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; SULPIRIDE; ZIPRASIDONE; ZOTEPINE;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERANCE; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEUROLOGIC DISEASE; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 0037269272     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0107     Document Type: Article

References (19)

1. Association of British Pharmaceutical Industry. Medicines Compendium 2002. London, UK: Datapharm Communications; 2001
2. Taylor D, Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics. J Psychopharmacol 2001;14:409-418
3. Taylor D, McConnell D, McConnell H, et al. The Maudsley Prescribing Guidelines. 6th ed. London, UK: Martin Dunitz Ltd; 2001
4. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary No. 42. London, UK: Royal Pharmaceutical Society, British Medical Association; 2001
5. Szymanski SR, Cannon TD, Gallacher F, et al. Course of treatment response in first-episode and chronic schizophrenia. Am J Psychiatry 1996;153:519-525
6. Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia: the effects of dose reduction and family management. Arch Gen Psychiatry 1997;54:453-463
7. Meltzer HY, Lee M, Cola P. The evolution of treatment resistance: biologic implications. J Clin Psychopharmacol 1998;18(suppl 1):5S-11S
8. Taylor D, Shapland L, Laverick G, et al. Clozapine: a survey of patient perceptions. Psychiatr Bull 2000;24:450-452
9. Pereira S, Beer D, Paton C. Enforcing treatment with clozapine: survey of views and practice. Psychiatr Bull 1999;23:342-345
10. Paton C, Garcia J, Brooke D. The use of atypical antipsychotics by consultant psychiatrists working in forensic settings. Psychiatr Bull 2002;26:172-174
11. Munro J, O'Sullivan D, Andrews C, et al. Active monitoring of 12760 clozapine recipients in the UK and Ireland. Br J Psychiatry 1999;175:576-580
12. Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998;155:499-504
13. Martin J, Gómez JC, García-Bemardo E, et al. Olanzapine in treatmentrefractory schizophrenia: results of an open-label study. J Clin Psychiatry 1997;58:479-483
14. Wirshing D, Marshall B, Green M, et al. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry 1999;156:1374-1379
15. Kinon BJ, Kane JM, Johns C, et al. Treatment of neuroleptic resistant schizophrenic relapse. Psychopharmacol Bull 1993;29:309-314
16. Joffe G, Rybak J, Burkin M, et al. Clozapine response in early treatment-resistant schizophrenia. Int J Psychiatry Clin Pract 1997;1:261-268
17. Szymanski S, Masiar S, Mayerhoff D, et al. Clozapine response in treatment-refractory first-episode schizophrenia. Biol Psychiatry 1994;35:278-280
18. Kane JM, Marder SR, Schooler NR, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a six month randomized and doubleblind comparison. Arch Gen Psychiatry 2001;58:965-972
19. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997;337:809-815